Vivos Therapeutics (VVOS) Tops Q2 EPS by 6c

Vivos Therapeutics (NASDAQ: VVOS) reported Q2 EPS of ($0.31), $0.06 better than the analyst estimate of ($0.37). Revenue for the quarter came in at $5.15 million versus the consensus estimate of $5.57 million.

For earnings history and earnings-related data on Vivos Therapeutics (VVOS) click here.

You May Also Be Interested In

• Vivos Therapeutics opens sleep center in Henderson, Nevada
• China semiconductor equipment imports grow 9% in July, Barclays comments
• Arctos agrees to buy 10% of Atlanta Falcons at $10.6 billion valuation - Bloomberg